MindWalk Holdings Corp. (HYFT)

Market Cap	75.49M +400.0%
Revenue (ttm)	20.70M +95.9%
Net Income	-9.03M
EPS	-0.20
Shares Out	49.67M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,574,938
Open	1.390
Previous Close	1.260
Day's Range	1.390 - 1.600
52-Week Range	0.475 - 3.246
Beta	0.65
Analysts	Strong Buy
Price Target	4.33 (+184.87%)
Earnings Date	Mar 12, 2026

About HYFT

MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock therapeutic possibilities. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 202...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 3, 2017
• Employees: 102
• Stock Exchange: NASDAQ
• Ticker Symbol: HYFT
• Website: https://www.mindwalkai.com

Financial Performance

In fiscal year 2025, MindWalk Holdings's revenue was 24.52 million, an increase of 0.01% compared to the previous year's 24.52 million. Losses were -30.23 million, 15.8% more than in 2024.

Financial numbers in CAD

Analyst Summary

According to 3 analysts, the average rating for HYFT stock is "Strong Buy." The 12-month stock price target is $4.33, which is an increase of 184.87% from the latest price.

Price Target

$4.33

(184.87% upside)

Analyst Consensus: Strong Buy